Bacterial meningitis: is there a "best" antimicrobial therapy?
The introduction of several cephalosporins into pediatric practice has provided the physician with a number of choices in the treatment of neonatal and childhood meningitis. Adequate studies are available to indicate that these new drugs are as effective as traditional treatments in terms of survival and major neurologic sequelae but it is not known whether the results are worse or better as far as the incidence of more subtle neurologic changes is concerned. The advantages of the cephalosporins in treatment of childhood meningitis are that they permit single drug therapy, the risks of drug toxicity are reduced, and the problems of penicillin-tolerant pneumococci and ampicillin/chloramphenicol-resistant H. influenzae are avoided. When used in the treatment of neonatal disease, the cephalosporins have the advantage of lower toxicity than the aminoglycosides, generally making blood drug level determinations unnecessary, and are effective against strains of bacteria that have become resistant to the latter drugs.
Eichenwald
H F
HF
D002438:Cefoperazone / Q000627:therapeutic use; D002442:Ceftazidime / Q000627:therapeutic use; D002443:Ceftriaxone / Q000627:therapeutic use; D002444:Cefuroxime / Q000627:therapeutic use; D002511:Cephalosporins / Q000627:therapeutic use*; D002648:Child; D006801:Humans; D007231:Infant, Newborn; D008581:Meningitis / Q000188:drug therapy*; D008583:Meningitis, Haemophilus / Q000188:drug therapy*; D009070:Moxalactam / Q000627:therapeutic use
D002511:Cephalosporins; D002443:Ceftriaxone; D002438:Cefoperazone; D002442:Ceftazidime; D002444:Cefuroxime; D009070:Moxalactam